This trial is active, not recruiting.

Condition schizophrenia, first-episode
Treatment risperidone, haloperidol
Phase phase 4
Sponsor Ludwig-Maximilians - University of Munich
Collaborator Janssen-Cilag Ltd.
Start date November 2000
End date December 2004
Trial size 300 participants
Trial identifier NCT00157378, 01GI9933-P2.1.2.1


The study is a multicenter, double-blind, randomized, parallel-group study with first episode schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with Risperidone or Haloperidol. Aim of the project is to compare the effects of the atypical neuroleptic Risperidone with those of the conventional neuroleptic Haloperidol and to evaluate whether the assumed advantages of atypical neuroleptics compared to conventional neuroleptics are also present when both medications are administered in rather low daily dosages (min. 2 mg/d; max. 8 mg/d).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

weekly assessment of psychopathology (e.g.PANSS)and side-effects
time frame:

Secondary Outcomes

cognitive disability
time frame:
time frame:
life quality at time of admission & end of study
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 55 years old.

Inclusion Criteria: - ICD-10 criteria for first episode schizophrenia - age between 18 and 55 - informed consent Exclusion Criteria: - legal reasons - insufficient knowledge of the german language - substance abuse or addiction - pregnancy - serious physical illness - organic brain disease - contraindication to neuroleptic treatment

Additional Information

Official title Optimization of Acute Treatment in First Episode Schizophrenic Patients by New Pharmacological Treatments
Description Considering that first episode schizophrenic patients compared to multiple episode patients respond to lower dosages of neuroleptics, the study aims to reach neuroleptic response under the lowest possible dosage of the study medication (haloperidol or risperidone). Therefore the initial dosage of the study medication is 2 mg/d. Depending on the patients` symptomatology, the daily dosage of the study medication can be increased by 2 mg in weekly intervals up to a maximum dosage of 8 mg/d. Patients with the diagnosis of schizophrenia (F20, according to ICD-10-criteria) are consecutively enrolled in the study. The patients are assessed at weekly intervals during the acute inpatient treatment phase of 8 weeks. Apart from the weekly psychopathological characterisation additionally neuropsychobiological data are assessed at the time of admission and at the end of the study. Major questions of the study are, whether patients, who have been treated with risperidone compared with those, who have been treated with haloperidol show a better treatment outcome regarding negative symptoms and exhibit fewer extra-pyramidal motor side effects. Furthermore it is hypothesised, that the treatment with Risperidone has better effects on cognitive disorders/dysfunctions and depressive symptoms and that the patients, who receive Risperidone are more compliant and have a higher quality of life.
Trial information was received from ClinicalTrials.gov and was last updated in September 2005.
Information provided to ClinicalTrials.gov by Ludwig-Maximilians - University of Munich.